BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29516013)

  • 1. Update of ALDH as a Potential Biomarker and Therapeutic Target for AML.
    Yang X; Yao R; Wang H
    Biomed Res Int; 2018; 2018():9192104. PubMed ID: 29516013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Blume R; Rempel E; Manta L; Saeed BR; Wang W; Raffel S; Ermakova O; Eckstein V; Benes V; Trumpp A; Ho AD; Lutz C
    Leuk Lymphoma; 2018 Sep; 59(9):2201-2210. PubMed ID: 29334844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
    Gerber JM; Smith BD; Ngwang B; Zhang H; Vala MS; Morsberger L; Galkin S; Collector MI; Perkins B; Levis MJ; Griffin CA; Sharkis SJ; Borowitz MJ; Karp JE; Jones RJ
    Blood; 2012 Apr; 119(15):3571-7. PubMed ID: 22262762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers.
    Gasparetto M; Smith CA
    Chem Biol Interact; 2017 Oct; 276():46-51. PubMed ID: 28645468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential.
    Cheung AM; Wan TS; Leung JC; Chan LY; Huang H; Kwong YL; Liang R; Leung AY
    Leukemia; 2007 Jul; 21(7):1423-30. PubMed ID: 17476279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
    Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
    Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ; Meel MH; Wouters F; Min LA; Terwijn M; de Jonge NA; Kelder A; Snel AN; Zweegman S; Ossenkoppele GJ; Smit L
    PLoS One; 2013; 8(11):e78897. PubMed ID: 24244383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALDH marks leukemia stem cell.
    Fleischman AG
    Blood; 2012 Apr; 119(15):3376-7. PubMed ID: 22500050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
    de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
    Bill M; Aggerholm A; Kjeldsen E; Roug AS; Hokland P; Nederby L
    Br J Haematol; 2019 Mar; 184(5):769-781. PubMed ID: 30520015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Emerging Roles of Aldehyde Dehydrogenase in Acute Myeloid Leukemia and Its Therapeutic Potential.
    Rahmati A; Goudarzi S; Sheikhi M; Siyadat P; A Ferns G; Ayatollahi H
    Anticancer Agents Med Chem; 2023; 23(3):246-255. PubMed ID: 35692153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment.
    Pierre-Louis O; Clay D; Brunet de la Grange P; Blazsek I; Desterke C; Guerton B; Blondeau C; Malfuson JV; Prat M; Bennaceur-Griscelli A; Lataillade JJ; Le Bousse-Kerdilès MC
    Stem Cells; 2009 Oct; 27(10):2552-62. PubMed ID: 19650038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
    Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
    Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in the leukemic stem cell study and a novel therapeutic approach targeting leukemic stem cells].
    Kikushige Y; Miyamoto T; Akashi K
    Rinsho Ketsueki; 2017; 58(10):1838-1843. PubMed ID: 28978822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.